MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients
On July 15, 2026, MediciNova, Inc., a biopharmaceutical company listed on the NASDAQ Global Market (NASDAQ: MNOV) and the Tokyo Stock Exchange (Code Number: 4875), disclosed that they have successfully reached the target enrollment of 200 patients in the SEANOBI-ALS study. This study, also known as Scalable Expanded Access with Analysis of Neurofilament and Other Biomarkers in ALS (NCT 06743776), is investigating the efficacy of MN-166 (ibudilast) in individuals with amyotrophic lateral sclerosis (ALS).